ArticlePharmaceutics2023
Bacteriocin-Nanoconjugates (Bac10307-AgNPs) Biosynthesized from
Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Vaginal Probiotic Potential ofGenes · 2026Article
- Pacin, a novel bacteriocin fromMicrobiology spectrum · 2026Article
- Cytotoxicity and antibacterial BioEffects of CuO-Zn nanoparticles synthesized from Lactobacillus helveticus yogurt isolates targeting RsbA gene expression.Scientific reports · 2026Article
- Natural, safety immunomodulatory derivatives of lactobacillus biofilms promote diabetic wound healing by metabolically regulating macrophage phenotype and alleviating local inflammation.Journal of advanced research · 2026Article
- Bacteriocins as a Promising Antimicrobial Strategy Against Multidrug-Resistant Pathogens: Mechanisms of Action, Applications in Human and Animal Health, and the Food Industry.BioMed research international · 2026Review
- Synthesis, Characterization, and Biomedical Applications of Bacteriocin-Selenium Nanoconjugates.Probiotics and antimicrobial proteins · 2025Article
- Biogenic-Synthesized Silver Nanoparticles Using the Ligilactobacillus salivarius KC27L Postbiotic: Antimicrobial, Anti-Biofilm, and Antioxidant Activity and Cytotoxic Effects.Probiotics and antimicrobial proteins · 2025Article
- The Mystery of CertainMicroorganisms · 2025Review
- Harnessing Nanoparticles to Overcome Antimicrobial Resistance: Promises and Challenges.Current pharmaceutical design · 2025Review
- ProbioticHeliyon · 2024Article
- Emerging lactic acid bacteria bacteriocins as anti-cancer and anti-tumor agents for human health.Heliyon · 2024Review
- Antagonistic Interactions of Lactic Acid Bacteria from Human Oral Microbiome againstMicroorganisms · 2023Article
- In Silico and in vitro Characterization ofIranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 4 countries.
Funding
Abstract
The proteinaceous compounds produced by lactic acid bacteria are called bacteriocins and have a wide variety of bioactive properties. However, bacteriocin's commercial availability is limited due to short stability periods and low yields. Therefore, the objective of this study was to synthesize bacteriocin-derived silver nanoparticles (Bac10307-AgNPs) extracted from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.